News|Podcasts|April 29, 2025
Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
Author(s)Alexandra Gerlach, Associate Editor
Pharmacists discuss how drug design impacts drug efficacy and indications for HER2-low and -ultra-low breast cancer.
Advertisement
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
3
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
4
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
5